|
 The event in New York - the company's first investor day centred on
drug development for more than a decade - will profile medicines
from a pipeline that is 80 percent first-in-class, Andrew Witty said
in a public interview at the Chatham House think-tank in London.
It will include an update on its Type 2 topoisomerase inhibitor drug
candidate, which is in the Phase II stage of development, according
to Witty.
He said that only two new classes of antibiotics - drugs which treat
bacterial infections - had been discovered in the past 40 years. "We
have a third one," he said.
(Reporting by Paul Sandle; Editing by Mark Heinrich)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
